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Approved CAR T cell therapies: ice
bucket challenges on glaring safety
risks and long-term impacts
Ping-Pin Zheng1,2, p.zheng.1@erasmusmc.nl, Johan M. Kros2 and Jin Li3
Two autologous chimeric antigen receptor (CAR) T cell therapies (KymriahTM and YescartaTM) were
recently approved by the FDA. KymriahTM is for the treatment of pediatric patients and young adults
with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and YescartaTM is for the
treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T
cell therapies lysing CD19-positive targets. Their dramatic efficacy in the short term has been
highlighted by many media reports. By contrast, their glaring safety gaps behind the miracles remain
much less addressed. Here, we focus on addressing the crucial challenges in relation to the gaps.
Drug Discovery Today Volume 00, Number 00 December 2018 PERSPECTIVEIntroduction
Two chimeric antigen receptor (CAR) T cell
therapies (KymriahTM and YescartaTM) were
recently approved by the FDA [1,2]. KymriahTM
(tisagenlecleucel) is for the treatment of pedi-
atric patients and young adults with refractory
or relapse (R/R) B cell precursor acute lym-
phoblastic leukemia (ALL), whereas YescartaTM
(axicabtagene ciloleucel) is for the treatment of
adult patients with R/R large B cell lymphoma.
They are both genetically modified autologous
T cells expressing a CD19-specific CAR, lysing
CD19-positive targets (normal and malignant B
lineage cells). A noted difference is shown in
the vectors used for KymriahTM (lentiviral vec-
tor) and YescartaTM (F-retroviral vector) [3].
The overall response rate (ORR) in the short
term was very high (83%), solely based on a
single infusion of KymriahTM [1], where leuke-
mia could not be cured by any other means,Please cite this article in press as: Zheng, P.P. et al. Approved C
doi.org/10.1016/j.drudis.2018.02.012
1359-6446/ã 2018 The Authors. Published by Elsevier Ltd. This is an o
https://doi.org/10.1016/j.drudis.2018.02.012 and patients went into remission within 3
months of being treated with KymriahTM. The
recipients of YescartaTM had 72% ORR [2]. Ob-
viously, there is no doubt about the lifesaving
potential of the treatments in these hopeless
cases. Numerous media reports have dramati-
cally highlighted the lifesaving potential of
KymriahTM and YescartaTM, and they have been
coined as ‘living drugs’.
Indeed, this is a history-rewriting progress in
cancer medicine and a quintessentially modern
paradigm of clinical oncology, which not only
gives hope but also directly drives innovative
cancer science to patient care and leads to a
paradigm shift from protocol-based treatment
to real-time personalized therapy unprece-
dentedly. However, in the real world, even
though a drug has a greater potency or a
medical technology provides dramatic benefits,
distinct and even serious adverse health risksAR T cell therapies: ice bucket challenges on glaring safety risks
pen access article under the CC BY license (http://creativecommons.orgcan be associated either predictably or unpre-
dictably [4]. It has been evident that many types
of anticancer drugs or modalities including
those modern ones with ‘breakthrough desig-
nation’ have induced life-threatening compli-
cations (e.g. cardiotoxicity) [5]. KymriahTM and
YescartaTM remain therefore not only with seri-
ous patient safety events already noted in the
short term but also with their long-term impacts
(efficacy and safety) lacking. As all the stake-
holders strive to understand the great successes,
in the meantime, we should keep in mind the
real-time challenges and realize gaps in the
dramatic efficacy versus glaring safety concerns.
Here, we analyze the crucial challenges re-
garding the gaps impacting quality-of-life (QOL)
with the therapies, and provoke intensive
debates especially regarding these potentially
long-simmering problems that have not yet
been fully explored. and long-term impacts, Drug Discov Today (2018), https://
/licenses/by/4.0/).
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and YescartaTM
Overall, the efficacy versus toxicity and safety of
a treatment manifests as short- and long-term
effects. Despite the excellent clinical responses
of the R/R B ALL patients to KymriahTM [1] and R/
R large B cell lymphoma patients to YescartaTM
[2], a significant number of patients treated by
KymriahTM have relapsed months later [6,7], and
nearly 30% of patients had a partial response
treated by YescartaTM and the therapeutic
effects tended to wane by the 6-month mark in
many [8]. Thus, it remains unknown as to how
long the benefits of KymriahTM and YescartaTM
might last (i.e. there are concerns about long-
term efficacy). Clinical relapse suggests that
cancer cells develop resistance to the destruc-
tion unleashed by the cytotoxic T lymphocytes
[9]. Many biological and biochemical factors
could potentially impact the efficacy and safety
of KymriahTM and YescartaTM (Table 1). However,
the definite causes underlying the immune re-
sistance or partial response are not fully un-
derstood. Some important factors possibly
accounting for the efficacy, resistance or ineffi-
cacy are formulated here.
Challenges in synthetic immunobiology
Expansion and persistence of the CAR-modified T
cells in the body are linked to many factors (Table
1). Any of these factors could collectively or in-
dividually influence the response in the patients
treated by KymriahTM and YescartaTM [7,10–20].
Formulation of T cell subsets
Each T cell subset has a unique cytokine profile,
functional properties and presumed roles in
pathogenesis [21] and holds a specific role in
protective immunity [22]. Functionally, T cells
can be identified as either beneficial tumor-
specific T cells or deleterious counterparts [22].
Thus, controlling the T cell subsets with favor-
able function compositions of a CAR T cell
product is one of the most important aspects for
manufacturing more-effective clinical T cell
products [10,22]. The strategy holds the po-
tential to reduce product variability, improves
the consistency of in vivo proliferation and
provides reproducible potency [11,15,19,22,23].
Moreover, T cell maturation status is important
as well, and it was found that less differentiated,
stem-cell-like T cells possess greater therapeutic
efficacy [24,25].
Immunosuppressive tumor
microenvironment
The immune system has a double-edged role,
being involved in suppressing tumor growth byPlease cite this article in press as: Zheng, P.P. et al. Approved C
doi.org/10.1016/j.drudis.2018.02.012
2 www.drugdiscoverytoday.comdestroying cancer cells and shaping the im-
munogenic phenotypes of tumors to promote
tumor progression by escaping immunosur-
veillance [9,26]. These inhibitory and immuno-
suppressive stimuli can impede the function of
CAR T cells [27] and ‘armored CARs’ could
improve T cell function [28].
CD19 variants (antigen-loss relapses)
CD19 ALL variants are being recognized with
increasing frequency, rendering the CAR T cells
ineffective against B cell tumors and thus repre-
senting a barrier to progress in CD19-directed
immunotherapy [29,30]. Several novel mecha-
nisms associated with CD19 ALL variants have
been discovered [6,31–33] (e.g. alternative mRNA
splicing, CD19 gene deletion or mutation, CD19-
negative clonal evolution, induction of a myeloid
switch). Allogeneic stem cell transplantation (allo-
SCT) and co-targeting of multiple markers on
leukemic cells could be the possible solutions [6].
But tumor-specific antigens are rare, and thus
multipletargetingpotentially increases off-tumor,
on-target toxicities [5] including neoreactivities
(allo-HLA and autoreactive activity) induced by
mixed T cell receptor (TCR) dimers [34].
CAR protein and RNA downregulation
CAR expression is decreased upon repeated
stimulations [24,35,36] or when there is accel-
erated differentiation and exhaustion of the T
cells [24,36]. These problems pose additional
challenges of CAR in CAR T cell therapy. A
possible solution for the problem is to direct a
CD19-specific CAR to the TCR a constant (TRAC)
locus by CRISPR/Cas9 genome editing [35],
which potentially yields some benefits (e.g.
decreased T cell differentiation and exhaustion
[22,37,38], minimizing the risks of insertional
oncogenesis and TCR-induced autoimmunity
and alloreactivity [35]).
High dose of corticosteroids
It is unclear whether tocilizumab has any bene-
ficial effects on neurotoxicities [39], because its
size makes efficient blood–brain barrier (BBB)
penetration unlikely [33,40]. Thus, the first-line
agent to treat severe neurotoxicities is often with
systemic corticosteroids rather than tocilizumab
[33,39]. However, prolonged use of high-dose
corticosteroids results in ablation of the CAR T cell
population [20,41]. Moreover, inappropriate use
of glucocorticoids is associated with risk for early
relapse of primary disease [41].
Extramedullary disease
The central nervous system (CNS) is a well-rec-
ognized reservoir wherein leukemia can escapeAR T cell therapies: ice bucket challenges on glaring safety riskssystemic cytotoxic therapy [42]. The CNS com-
partment is affected in roughly one-third of ALL
relapses [43,44], whereas CNS involvement at
relapse occurs mainly in patients who were CNS-
negative at initial diagnosis [44,45]. Intriguingly,
CD19 CAR T cells have been identified in the
cerebrospinal fluid (CSF) of patients after infu-
sion [46–48], even though many of the patients
(80%) did not have a history of CNS leukemia
[49], suggesting the ability of these cells to cross
the BBB [47,50]. Thus, the therapy might be
considered to replace multiple doses of either
prophylactic or therapeutic, intrathecal che-
motherapy and radiation in leukemia patients.
Theoretically, the replacement could reduce
cognitive impairment and developmental delay
resulting from chemotherapy and radiation in
the patient population, because ALL is most
commonly diagnosed in children under 8 years
of age, a crucial time in brain development [51].
However, a contradictory event in parallel con-
sideration is neurotoxicity – one of the major
complications of KymriahTM and YescartaTM. As a
result, caution should always be taken when
considering the replacement. Furthermore, de-
tection of CD19 expression in the brain paren-
chyma remains controversial [25], and thus the
capacity for clearance of Extramedullary disease
(EMD) by the therapy remains uncertain [22] and
further research in this area is warranted.
Common toxicities of KymriahTM,
YescartaTM and beyond
Given the extreme potency of the CAR-modified
T cells and similar mode of action, the use of
KymriahTM and YescartaTM harbors common
fatal toxic potentials that can be as bad as or
worse than the original condition and even
lethal [1,2,10]. Some higher rates of serious
adverse events manifested in acute or subacute
forms have been demonstrated as immediately
life-threatening [1,2,10] (Table 2). Because the
cellular immune system has been artificially
boosted for an enhanced activation, KymriahTM
and YescartaTM act like ‘immuno-bombs’, remi-
niscent of the atomic bombing in Hiroshima and
Nagasaki in 1945, and the immuno-bombs drop
into the circulation system of the human body
to nonspecifically destroy cancer cells and their
innocent counterparts. Effective prevention of
these acute and subacute toxicities (e.g. CRS:
Cytokine-release syndrome and NT: neurotox-
icity) remains unfeasible, because either the
mechanisms of these toxicities remain poorly
understood (e.g. NT) [22] or CAR T products have
endogenously inherited features (e.g. CRS). To
date, palliative supportive care (PSC) and im-
munosuppression remain the only approaches and long-term impacts, Drug Discov Today (2018), https://
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TABLE 1
Potential biological and biochemical factors impacting the efficacy and safety of KymriahTM and YescartaTM
Potential factors Potential mechanisms or causes Major possible effects Possible solutions and remarks Refs
Number of the transduced T cells Transduction efficiency Impact the reproducible potency Control vector copy and CAR expression [7,20]
Cell lineage and differentiation
state
Component variability of the
product
Impact the reproducible potency Improve production method
[7,11,15,20,28,38]
Cell viability Nonviable cells Impact the efficacy and safety profile Improve production method [7,10]
Cellular impurities Non T cells (B lineage cells, blasts
and others)
Impact the efficacy and safety profile Improve production method [7,10]
Excipients (DMSO, dextran 40) Anaphylaxis Impact the safety profile Improve production method [1,7,10]
Manufacturing failures Poor starting autologous
leukapheresis cells
Jeopardize disease control and survival Use universal CAR19 T cells [7,10,18]
Specificity of the scFv domain Determinant for the CAR T cell
safety profile
Off-target activity and B cell aplasia Use therapeutic immunoglobulin, anti-
FcmR CAR T, RNA CARs
[7,14,20]
Affinity of scFv binding CAR T cell activation and effector
functions
Impact the safety and activity Not restricted by MHC (applicable to any
MHC haplotype)
[7]
Functional T cell subsets and
ratios
Component variability of the
product
Impact the reproducible potency Improve production method
[7,11,20,22]
IFN-g production A prerequisite for CAR T cell activity An indicator of T cell activation In vitro data may not correlate to in vivo
efficacy, technical advances
[7]
CAR signaling domains and
spacer variants
Off-target T cell activation Impact the safety and activity (CD19-
independent toxicities)
Biological optimization
[7,12,13,16,17,20]
Decreased CAR expression Repeated stimulations, accelerated
diff/ex
Reduced efficacy TRAC-CAR to decrease differentiation of T
cells, other approaches
[24,35,36]
T cell dose versus tumor burden An inverse correlation Impact the expansion and persistence Bridging therapy to reduce tumor burden
before KymriahTM
[11,28]
Immunosuppressive
environment
Inhibitory and immunosuppressive
stimuli
Impede the function of CAR T cells ‘Armored’ CAR T cells to enhance IS, risk of
cumulative toxicities
[22,30]
CD19-negative variants CD19 del/mut, CD19 clonal
evolution, lineage switch
Inefficacy Target multiple antigens, allo-HSCT, risk of
cumulative toxicities
[23,30–
34,55]
Anti-mCAR19 antibodies Immunogenicity Immunity anaphylaxis, impact the
efficacy and safety profile
Use human anti-CD19 CAR (HuCAR-19) [1,7]
Extramedullary disease (EMD) Sanctuary site relapse (e.g. CNS) Uncertain capacity for clearance of EMD Further studies for confirmation [22,25]
Lymphodepletion chemotherapy Conditioning regimen to reduce
tumor burden
Augment the antitumor effects Risk of cumulative toxicities [7,11,28]
High dose of corticosteroids Impede CAR T cell function Diminished efficacy owing to
immunosuppression
Tocilizumab, uncertain effects for
neurotoxicities
[20]
Abbreviations: IS, immune system; DMSO, dimethyl sulfoxide; MHC, major histocompatibility complex; IFN-g, interferon gamma; TRAC, T cell receptor a constant locus; diff, differentiation; ex, exhaustion; del, deletion; mut, mutation; scFv,
single-chain variable fragment; allo-HSCT, allogeneic stem cell transplantation; CNS, central nervous system.
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TABLE 2
Common acute and subacute toxicities (incidences >50%, 20%, 10% and 2%) and long-term risks of KymriahTM and YescartaTM
Toxicities (T) and risks (R) Category 50% 20% 10% 2% Clinical form Potential mechanisms/
causes
Management
strategies and
comments
Refs
CRS T + Short term Activated T cells produce
high levels of cytokines
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Neurotoxicities T + Short term Unknown Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Serious infection T + Short term Acquired
hypogammaglobulinemia Familiar with FDA
labels, REMS and
ETASU
[1,2,7]
Prolonged cytopenias T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Acquired hypogammaglobulinemia T + Short term On-target off-tumor
toxicities (B cell aplasia)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Humoral immunogenicity T + Short term Anti-mCAR19 antibodies Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Tachycardia T + Short term Miscellaneous cause (e.g.
CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Gastrointestinal disorders T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Acute kidney injury T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Acute respiratory distress T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Musculoskeletal disorders T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Hypotension T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Hypertension T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Cardiac failure or arrest T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
TLS T + Short term Large amounts of tumor
cells lysed
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
DIC T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
MAS T + Short term Uncontrolled activation
of macrophages and T
cells
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Capillary leak syndrome (bleeding) T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
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TABLE 2 (Continued )
Toxicities (T) and risks (R) Category 50% 20% 10% 2% Clinical form Potential mechanisms/
causes
Management
strategies and
comments
Refs
Coagulopathy T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
Hypofibrinogenemia T + Short term Miscellaneous causes (e.
g. CRS)
Familiar with FDA labels,
REMS and ETASU
[1,2,7]
GVHD R 1% Undefined Residual donor
lymphocytes from prior
HSCT
Warning and intensive
monitoring
[7]
Anaphylaxis R Undefined Excipients (e.g. DMSO,
dextran)
Warning and intensive
monitoring
[1,2,7]
Secondary malignancies R Long term Insertional oncogenesis
and genotoxicity
Warning and lifelong
monitoring
[1,2,7]
Developmental and reproductive toxicity R Long term Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warning and lifelong
monitoring
[1,2,7]
New incidence of neurologic disorders R Long term Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warning and lifelong
monitoring
[1,2,7]
Exacerbation of pre-existing neurologic disorders R Long term Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warning and lifelong
monitoring
[1,2,7]
New incidence of autoimmune disorders R Long term Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warning and lifelong
monitoring
[1,2,7]
Exacerbation of prior autoimmune disorders R Long term Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warning and lifelong
monitoring
[1,2,7]
Incidence and outcome of any pregnancy R Undefined Miscellaneous causes (e.
g. DAMPs, prolonged
CRS)
Warnings and
monitoring during the
pregnancy
[1,2,7]
Abbreviations: CRS, cytokine release syndrome; TLS, tumor lysis syndrome; DIC, disseminated intravascular coagulation; MAS, macrophage activation syndrome; GVHD, graft-versus-host disease; DAMPS, damage-associated molecular
patterns; HSCT, hematopoietic stem cell transplantation; REMS, Risk Evaluation and Mitigation Strategy; ETASU, Elements to Assure Safe Use.
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even considering the latest new guidelines [52].
Recently, a human study explored the mecha-
nism of NT and suggested that an increased BBB
permeability might explain NT [53]. The study
could lead to further studies for development of
novel treatment on the basis of mechanisms. B
cell aplasia (acquired hypogammaglobulinemia)
is an on-target off-tumor toxicity for CD19-tar-
geted CAR [1,2] (i.e. a specific toxicity of CD19
CAR T) because CD19 is a cell-surface compo-
nent of B cell lineage [3]. There are several
possible solutions to potentially overcoming or
minimizing B cell aplasia: (i) use of anti-FcmR
CAR T [14]; (ii) use of RNA CARs [20]; (iii) infusion
of pooled immunoglobulins [1,2]. Beyond this,
additive side-effects (secondary or tertiary
toxicities) derived from combining or bridging
agents should not be overlooked (e.g. tocilizu-
mab with an FDA warning and precaution labels
[54], ibrutinib to prevent CRS after using anti-
CD19 CART [55] with known cardiac concerns [5]
and other serious complications [56,57]). Fur-
thermore, the use of host lymphodepletion
chemotherapy with immunosuppressive agents
(e.g. cyclophosphamide) before a CAR T ap-
proach is a required step to augment the anti-
tumor effects of this treatment [1,2,5,7].
However, such concomitant therapies can lead
to clinical cardiotoxicity [5]. Consequently, these
combining or bridging agents might increase
some cumulative or synergistic toxicities for the
patients.
Uncertain long-term outcomes of
KymriahTM and YescartaTM
Data were fast-emerging on the early responses
to KymriahTM and YescartaTM, thus most of the
patients participating in the trials have only
been followed for a relatively short period of
time [1,2], limiting the ability to assess the risk
of long-term adverse events and rule them out.
As a result, long-term sequelae and late toxic
effects of KymriahTM and YescartaTM remain
unknown although some are theoretically
predictable (Table 2). Theoretically, the after-
math of the immuno-bombing in the human
body can be just as deadly and far-reaching,
because these cellular and molecular fallouts
from these damaged leukemia cells and their
normal counterparts in the blood circulation
reach as far as any systemic organs. Such
damage to normal cells and tissues might be
long-term and probably permanently toxic
[7,58]. This is in-line with the rationale that the
immune system not only responds to foreign
substances (i.e. pathogens) but also responds
to endogenously derived molecules that arePlease cite this article in press as: Zheng, P.P. et al. Approved C
doi.org/10.1016/j.drudis.2018.02.012
6 www.drugdiscoverytoday.comexpressed as a result of tissue damage or
stressed cells, known as damage-associated
molecular patterns (DAMPs) [59], which can
cause various diseases (e.g. autoimmune dis-
eases) [60,61]. Further, late onset of NT is an-
other concern for cognitive dysfunction. Little
is known about timing of the secondary and/or
tertiary toxicities resulting from DAMPs. Re-
ferring to the pathogenesis and long-term
course of many autoimmune diseases and
neurocognitive disorders, a chronic, progres-
sive disease process should be anticipated.
Given the extreme importance to the young
patient population uniquely targeted by Kym-
riahTM, it is worth knowing that classical gen-
otoxicity assays and carcinogenicity assessment
in vivo (rodent models) were not performed for
KymriahTM [7,10]. Developmental and repro-
ductive toxicity studies were not conducted in
the nonclinical studies for KymriahTM either
[7,10]. Thus, detection of long-term problems
as such will not only be dependent on a long-
term follow-up but also enhanced clinical
awareness and sensitive detection algorithms
are required for a goal-oriented evaluation.
Taken together, the safety profiles and the toxic
potential of KymriahTM and YescartaTM cannot
be assessed in isolation for short-term moni-
toring and management but need to be con-
sidered together with a long-term follow-up.
Lifesaving versus QOL-preserving of
KymriahTM and YescartaTM
Immune-cell-based therapies open a new fron-
tier for cancer treatments. But the changing
landscape of medical benefits and risks creates
new challenges for all the stakeholders in
healthcare owing to potentially lethal side
effects of the therapies and uncertain long-term
impacts on QOL. Currently, because the data
about the long-term impacts of KymriahTM and
YescartaTM are not available yet, there is insuf-
ficient voice to claim much more benefits than
medically acknowledged, instead of being in-
creasingly aware of the short- and long-term
risks [58]. Media reports often state dispropor-
tionately on risk by overstating benefits while
understating the harms [4,58]. Nevertheless, the
FDA plays a central part as an authoritative voice
in communicating the benefits and risks of a
drug [4]. It is important for all the stakeholders to
become familiar with the FDA labels containing
a Risk Evaluation and Mitigation Strategy (REMS)
and an Elements to Assure Safe Use (ETASU)
[1,2,7,10]. Lifesaving care and preserving patient
QOL are the tasks of modern medicine, being
especially important for the patient populations
of children and young adults. As more infor-AR T cell therapies: ice bucket challenges on glaring safety risksmation about treatment options becomes
available, patients, physicians, regulators and
payers are reassessing how they balance the
possible benefits and risks of therapeutic
options [4]. Theoretically, no patients expect any
treatment of procedure that is disproportion-
ately costly, burdensome or painful [62]. How-
ever, practically, when doctors treat patients
with life-threatening conditions (e.g. lethal
cancers), the major focus would often be quickly
directed toward instituting therapeutic mea-
sures to preserve life (lifesaving), and often they
are unable to address the impact of medical care
on QOL until after the lifesaving intervention
[63]. KymriahTM and YescartaTM were regarded
as a lifesaving treatment (a last-resort treatment)
[1,2] and fall within the scope of a formal debate
in this regard. Ironically, where advances in
technology and knowledge have given doctors
an increased capacity to preserve and prolong
life, some fundamental ethical questions could
be raised in parallel: should doctors be con-
cerned only with curing disease (lifesaving)? Do
they have a responsibility to give the patients
the best possible QOL while being physically or
fiscally reasonable [63]? These ethical dilemmas
might have to be addressed at the clinic door
that impacts individual patients by a participa-
tive management involving patients, doctors
and other stakeholders. In this context, an eth-
ical imperative requires classification of the
medical significance of an intervention espe-
cially when the intervention remains contro-
versial and underexamined, which will benefit
from decreasing the uncertainty associated with
the intervention.
Concluding remarks and future
perspectives
KymriahTM and YescartaTM gained ground as
last-resort treatments for R/R pediatric ALL and
R/R adult B cell lymphoma, respectively, owing
to their lifesaving potentials. The broad appli-
cations remain challenging because of acute
lethal toxicities and also uncertain long-term
impacts. Post-approval pharmacovigilance is
crucial as one of the first considerations for risk
mitigation of these known short-term toxicities.
Long-term follow-up for durable efficacy and
safety concerns is pending further progress.
Furthermore, advances in manufacturing pro-
cesses could reveal the better version of T-cell-
based therapies, even beyond cancer therapy, to
extrapolate the approach to treatment of in-
fectious and autoimmune diseases. To this end,
all efforts should be channeled into turning the
ice bucket challenges into solutions and
opportunities. and long-term impacts, Drug Discov Today (2018), https://
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